Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform.

"At Neomorph, we have spent years building a unique molecular glue platform ... "We are thrilled to partner with AbbVie, a global leader in delivering transformative medicines in oncology and ...

Collaboration leverages AbbVie's expertise in oncology and immunology ... "At Neomorph, we have spent years building a unique molecular glue platform with broad coverage of the proteome," said ...